Quarterly report pursuant to Section 13 or 15(d)

Impact of COVID-19 (Details)

v3.21.2
Impact of COVID-19 (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Unusual or Infrequent Item, or Both [Line Items]          
Total revenues $ 442,408 $ 301,207 $ 987,573 $ 512,674  
Genomic Test          
Unusual or Infrequent Item, or Both [Line Items]          
Change in testing volume (as a percent)     39.00%    
Routine Clinical Test          
Unusual or Infrequent Item, or Both [Line Items]          
Change in testing volume (as a percent)     13.40%    
Services          
Unusual or Infrequent Item, or Both [Line Items]          
Increase in revenue     $ 482,300    
Total revenues 397,197 250,971 904,149 421,811  
Transfer of intellectual property and other          
Unusual or Infrequent Item, or Both [Line Items]          
Total revenues $ 9,548 20,880 $ 13,816 $ 30,433  
CMS Accelerated and Advanced Payment Program, COVID-19          
Unusual or Infrequent Item, or Both [Line Items]          
Proceeds from issuance of debt   $ 14,000      
Distribution to Healthcare Providers, COVID-19          
Unusual or Infrequent Item, or Both [Line Items]          
Proceeds from issuance of debt         $ 16,200
Distribution to Healthcare Providers, COVID-19 | Transfer of intellectual property and other          
Unusual or Infrequent Item, or Both [Line Items]          
Total revenues         $ 16,200